Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Harry Meade currently holds 29,452 shares of GTC BIOTHERAPEUTICS INC (GTCB), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Harry Meade has been a net buyer of GTCB stock. They have purchased $9.0K and sold $0 worth of shares.
Harry Meade's most recent insider trade was on Nov 2, 2009, when they sold 13,598 shares at $1.21 per share.
Harry Meade serves as Executive at GTC BIOTHERAPEUTICS INC (GTCB). They have executed 10 insider transactions totaling $9.0K over their tenure at the company.
Harry Meade holds the position of Executive at GTC BIOTHERAPEUTICS INC, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 20 years and currently hold a stake valued at $0.
Harry Meade has shown a buying trading pattern, with $9.0K in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Harry Meade was on Nov 2, 2009, when they purchased $18.6K worth of GTCB shares. This transaction involved 15,403 shares at $1.21 per share.
Harry Meade currently owns 29,452 shares of GTC BIOTHERAPEUTICS INC (GTCB), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Harry Meade's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Harry Meade has 10 Form 4 filings on record as an insider at GTC BIOTHERAPEUTICS INC.
Set alerts for Harry Meade and 40,000+ other insiders.